![]() | This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Valsartan.
|
The Valsartan page is already being vandalized. cf. 'to give cancer after a heart attack' phrase in first para. You might want to lock it down for the time being Johnnyrev ( talk) 23:40, 16 July 2018 (UTC)
This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available
on the course page. Student editor(s):
Valsartan18,
Llaw18,
Jps18,
Evanescerovalsartan18. Peer reviewers:
Yamahaguy17,
RxDream17,
ChemERx17,
LilSteps 17.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT ( talk) 12:14, 17 January 2022 (UTC)
This article was the subject of a Wiki Education Foundation-supported course assignment, between 27 August 2019 and 13 December 2019. Further details are available
on the course page. Student editor(s):
Nrich1996,
Razmusj1.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT ( talk) 12:14, 17 January 2022 (UTC)
Could somebody with more medical experience please comment on the current state of this MI controversy? As a pharmacy student, I was never made aware of this controversy before and see that ARBs are still considered first line in HTN and alternative to ACEi in other indications. I found some meta-analyses that find that ARBs do not cause additional MI or other effects. However, there is controversy regarding the efficacy of ARBs when compared to ACEi simply due to the lack of clinical studies. [1] [2]
Because I don't have experience in the matter and only did a cursory pubmed search on the topic, I did not feel justified in adding it to wikipedia without some feedback, especially because I may be biased in the manner due to what my educational background taught me. Thanks! Zileu ( talk) 18:27, 3 November 2014 (UTC)
References
Hi all, this is Group 18 from CP133 2015 at UCSF School of Pharmacy. Some edits we have made:
I am interested to include a small paragraph on the recent valsartan generica recall in Europe (EMA) and the US. Since we are writing for the public, this would be of great interest. But it relates to the manufacturing of the the drug, I can't go too much into detail. But the recall is quite important due to the N-Nitrosodimethylamine impurity from a changed manufacturing process. Osterluzei ( talk) 02:42, 14 July 2018 (UTC)
The current page is a good improvement!
![]() | This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Valsartan.
|
The Valsartan page is already being vandalized. cf. 'to give cancer after a heart attack' phrase in first para. You might want to lock it down for the time being Johnnyrev ( talk) 23:40, 16 July 2018 (UTC)
This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available
on the course page. Student editor(s):
Valsartan18,
Llaw18,
Jps18,
Evanescerovalsartan18. Peer reviewers:
Yamahaguy17,
RxDream17,
ChemERx17,
LilSteps 17.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT ( talk) 12:14, 17 January 2022 (UTC)
This article was the subject of a Wiki Education Foundation-supported course assignment, between 27 August 2019 and 13 December 2019. Further details are available
on the course page. Student editor(s):
Nrich1996,
Razmusj1.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT ( talk) 12:14, 17 January 2022 (UTC)
Could somebody with more medical experience please comment on the current state of this MI controversy? As a pharmacy student, I was never made aware of this controversy before and see that ARBs are still considered first line in HTN and alternative to ACEi in other indications. I found some meta-analyses that find that ARBs do not cause additional MI or other effects. However, there is controversy regarding the efficacy of ARBs when compared to ACEi simply due to the lack of clinical studies. [1] [2]
Because I don't have experience in the matter and only did a cursory pubmed search on the topic, I did not feel justified in adding it to wikipedia without some feedback, especially because I may be biased in the manner due to what my educational background taught me. Thanks! Zileu ( talk) 18:27, 3 November 2014 (UTC)
References
Hi all, this is Group 18 from CP133 2015 at UCSF School of Pharmacy. Some edits we have made:
I am interested to include a small paragraph on the recent valsartan generica recall in Europe (EMA) and the US. Since we are writing for the public, this would be of great interest. But it relates to the manufacturing of the the drug, I can't go too much into detail. But the recall is quite important due to the N-Nitrosodimethylamine impurity from a changed manufacturing process. Osterluzei ( talk) 02:42, 14 July 2018 (UTC)
The current page is a good improvement!